RecruitingPhase 4NCT07310797

Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion

A Randomized Controlled Trial Comparing Mirabegron and Tamsulosin for Ureteral Stone Expulsion and Clinical Symptom Improvement


Sponsor

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Enrollment

500 participants

Start Date

Feb 13, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized controlled trial compares the efficacy and safety of four treatment strategies for ureteral stone expulsion: Mirabegron alone, Tamsulosin alone, a combination of both, and standard conservative care. Participants diagnosed with ureteral stones will be randomly assigned to one of these four groups. The primary objective is to evaluate the stone expulsion rate within 4 weeks. The study also assesses time to expulsion, pain intensity, analgesic use, and potential side effects.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mirabegron and a drug called Tamsulosin for people with ureteral calculi. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMirabegron

50 mg tablet orally once daily.

DRUGTamsulosin

0.4 mg tablet orally once daily.


Locations(1)

Taipei Tzu Chi Hospital

New Taipei City, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07310797


Related Trials